Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis.

Conversely, in the abatacept group, a higher proportion of good responders was observed among SE-positive patients, although this finding did not reach statistical significance (OR = 3.67 [0.92–24.71], P = 0.067) (Table 4 ).

also in 61,332 other papers

We observed a negative trend in the association, although not statistically significant, between the HLA-DRB1 *09:01 allele, which is the second significant risk allele in Korean RA population, and treatment response to abatacept (OR = 0.19 [0.01–1.11], P = 0.068) or TNFi (OR = 1.09 [0.61–1.92], P = 0.78) 5 .

also in 2,315 other papers